This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
Suicidal ideation and behavior in clinical trials are rare. For the above analysis, the FDA combined the results of 295 trials of 11 antidepressants for psychiatric indications in order to obtain statistically significant results. Considered separately, sertraline use in adults decreased the odds of suicidal behavior with a marginal statistical significance by 37%  or 50%  depending on the statistical technique used. The authors of the FDA analysis note that "given the large number of comparisons made in this review, chance is a very plausible explanation for this difference".  The more complete data submitted later by the sertraline manufacturer Pfizer indicated increased suicidal behavior.  Similarly, the analysis conducted by the UK MHRA found a 50% increase of odds of suicide-related events, not reaching statistical significance, in the patients on sertraline as compared to the ones on placebo.  
Most of the narrow spectrum agents are effective for localization-related or focal epilepsies. As an example, gabapentin (a narrow spectrum agent) may work well for a patient with temporal lobe epilepsy (a focal epilepsy), but is unlikely to be effective in juvenile myoclonic epilepsy (a generalized epilepsy). Ethosuximide is another narrow spectrum agent used for absence seizures (a generalized epilepsy), which is generally ineffective for focal seizures. Broad spectrum agents are effective for both types of epilepsies [ 79 ]. If the clinician is unsure whether the epilepsy syndrome is focal or generalized, a broad spectrum agent is usually chosen ( table 3 ).